Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294487 | 0.86 | CYP3A4 (0.36) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL4303686 | 0.83 | KDM4E (0.33) | ALDH1A1LMNATSHR | |
| SCHEMBL3860262 | 0.81 | HSD17B10 (0.38) | — | |
| SCHEMBL4302268 | 0.79 | PRPS1 (0.33) | — | |
| SCHEMBL2512106 | 0.79 | KCNH2 (0.42) | USP2ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL2799084 | 0.79 | ALDH1A1 (0.40) | USP2ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL4146040 | 0.79 | KCNH2 (0.40) | USP2ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL4297370 | 0.77 | CYP1A2 (0.41) | USP2ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL4146184 | 0.77 | ALDH1A1 (0.34) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3520140 | 0.77 | KCNH2 (0.41) | USP2ALDH1A1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | AR, RCC2, NR3C2 | USP2 3713/4885ALDH1A1 1227/4885LMNA 4334/4885 |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | USP2 3489/4885ALDH1A1 3885/4885LMNA 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.